This article first appeared on GuruFocus .
-
Capitated Revenue:$341.6 million for the quarter, approximately $982 per member per month.
-
Adjusted EBITDA Loss:$45.9 million for the quarter; year-to-date loss of $85.2 million.
-
Normalized Adjusted EBITDA Loss:Approximately $70 million year-to-date.
-
Medical Margin:$4.4 million for the quarter, or $13 per member per month.
-
Operating Expense:$21.1 million for the quarter, a 33% improvement from the prior year period.
-
Cash Position:$37.7 million at the end of the quarter.
-
Membership:Approximately 116,000 members for the quarter.
-
Full Year Adjusted EBITDA Guidance:Revised to a loss range of $110 million to $95 million.
Release Date: November 14, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Capitated revenue increased by approximately 6%, indicating positive growth in revenue streams.
-
Operational improvements led to over $100 million in EBITDA improvement year over year.
-
A strategic joint venture is expected to add approximately 13,000 fully accreted ACO members, enhancing profitability and cash flow.
-
The care enablement model is improving documentation accuracy, quality performance, and care coordination.
-
Stable medical cost trends have been maintained, reflecting effective clinical execution and cost management.
Negative Points
-
Adjusted EBITDA loss for the quarter was $45.9 million, with a year-to-date loss of $85.2 million.
-
Guidance for full-year adjusted EBITDA was revised to a loss range of $110 million to $95 million.
-
Mid-year settlement adjustments resulted in a $21 million unfavorable impact on Q3 revenue.
-
Challenges remain with non-core assets and specific markets, affecting overall performance.
-
There is ongoing pressure to renegotiate contracts and align provider networks to improve margins.
Q & A Highlights
Q: Can you elaborate on the renegotiation efforts with payers and what motivates them to adjust their margins? A: Aric Coffman, CEO, explained that payers are motivated by the need for assistance with high-risk patients, net expense reduction, and quality improvements. The renegotiations are driven by the value P3 Health Partners provides in these areas, which aligns with the payers' goals for margin improvement and quality outcomes.
Q: Are all contracts for 2026 full capitation, and how do you ensure payers have more involvement in medical management? A: Aric Coffman confirmed that P3 Health Partners takes on the risk from payers, who receive an administrative margin. The focus is on executing business operations and achieving star performance metrics. The partnership with payers involves bilateral accountability for outcomes, with increased meeting frequency and visibility to align expectations.
Q: Was the guidance reduction driven by issues with a specific payer or market, or was it more broad-based? A: Amir Bacchus, Chief Medical Officer, stated that the guidance reduction was broad-based, primarily due to mid-year settlements being less than expected and some medical cost initiatives being delayed. Structural controls have been implemented to improve future processes.
Q: What was the impact of prior period adjustments in the third quarter, and how will this be addressed in the future? A: Amir Bacchus noted a $3 million headwind from prior period adjustments, with a $21 million mid-year true-up impacting Q3. Improvements in data handling and communication with payers are expected to prevent similar issues in the future.
Q: What are the expectations for PMPM revenue growth in 2026, considering coding improvements and rate increases? A: Aric Coffman indicated a 5% net improvement in premium rates across their markets, with further insights into coding improvements expected in the next quarter. The 5% increase is based on base rate improvements, not including coding enhancements.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
